Novo Nordisk A/S ADR (NVO) |
|
95.16 -0.28 (-0.29%)
|
01-26 00:16 |
|
Open: |
94.19 |
Pre. Close: |
95.44 |
|
High:
|
95.87 |
Low:
|
93.99 |
|
Volume:
|
2,575,469 |
Market Cap:
|
216,755M |
|
|
|
|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
95.992 - 96.458 |
96.458 - 96.918 |
|
Low:
|
92.608 - 93.197 |
93.197 - 93.777 |
|
Close:
|
94.063 - 95.002 |
95.002 - 95.928 |
|
Technical analysis |
as of: 2022-01-25 4:26:03 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 122.34  One year: 131.88 |
| Support: |
Support1: 91.52 Support2: 76.14 |
| Resistance: |
Resistance1: 104.74 Resistance2: 112.91 |
| Pivot: |
99.18 |
| Moving Average: |
MA(5): 95.74 MA(20): 102.10
MA(100): 105.38 MA(250): 90.82 |
| MACD: |
MACD(12,26): -3.77 Signal(9): -3.20 |
| Stochastic oscillator: |
%K(14,3): 15.81 %D(3): 9.30 |
| RSI: |
RSI(14): 28.81 |
| 52-week: |
High: 117.35 Low: 66.59 Change(%): 36.7 |
| Average Vol(K): |
3-Month: 1317 10-Days: 1677 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.NVO has closed above bottom band by 20.1%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 10 Jan 2022
Novo Nordisk A/S – Share repurchase programme - GlobeNewswire
Mon, 10 Jan 2022
My Nifty 50 Stock Portfolio - Seeking Alpha
Fri, 17 Dec 2021
Novo Nordisk cites supply issues in the U.S. for weight loss therapy - Seeking Alpha
Mon, 13 Dec 2021
NVO (Novo Nordisk A/S ADR) - Morningstar.com
Fri, 26 Nov 2021
Novo Nordisk announces impact from Volume Based Procurement - GlobeNewswire
Thu, 18 Nov 2021
Novo Nordisk Agrees to Buy Dicerna Pharma for $3.3 Billion - TheStreet
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
2,280 |
| Shares Float (M) |
1,630 |
|
% Held by Insiders
|
0.01 |
|
% Held by Institutions
|
7.75 |
|
Shares Short (K)
|
2,810 |
|
Shares Short P. Month (K)
|
1,910 |
Stock Financials |
|
EPS
|
3.070 |
|
EPS Est This Year
|
2.420 |
|
EPS Est Next Year
|
2.590 |
|
Book Value (p.s.)
|
28.850 |
|
Profit Margin
|
34.31 |
|
Operating Margin
|
42.00 |
|
Return on Assets (ttm)
|
22.5 |
|
Return on Equity (ttm)
|
73.5 |
|
Qtrly Rev. Growth
|
15.2 |
|
Gross Profit (p.s.)
|
46.496 |
|
Sales Per Share
|
59.035 |
|
EBITDA (p.s.)
|
26.500 |
|
Qtrly Earnings Growth
|
17.70 |
|
Operating Cash Flow (M)
|
58,190 |
|
Levered Free Cash Flow (M)
|
32,650 |
Stock Valuations |
|
PE Ratio
|
31.00 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.30 |
|
Price to Sales
|
1.61 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
9.350 |
|
Forward Dividend
|
1.470 |
|
Dividend Yield
|
0.10 |
|
Dividend Pay Date
|
2021-08-24 |
|
Ex-Dividend Date
|
2021-08-15 |
|
7 Binary Options
|
|
Your Ad Here
|
|
